Biocept Valuation
| BIOCQ Stock | 0.0001 0.0001 50.00% |
Biocept seems to be undervalued based on Macroaxis valuation methodology. Our model approximates the value of Biocept from analyzing the firm fundamentals such as Shares Outstanding of 2.63 M, return on equity of -1.87, and Operating Margin of (10.38) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Biocept's valuation include:
Price Book 0.2852 | Enterprise Value | Enterprise Value Ebitda (0.16) | Price Sales 0.0004 | Enterprise Value Revenue 0.0417 |
Undervalued
Today
Please note that Biocept's price fluctuation is out of control at this time. Calculation of the real value of Biocept is based on 3 months time horizon. Increasing Biocept's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Biocept's intrinsic value may or may not be the same as its current market price of 0.0001, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.0E-4 | Real 3.37E-4 | Hype 9.4E-5 | Naive 4.26E-4 |
The intrinsic value of Biocept's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Biocept's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Biocept helps investors to forecast how Biocept stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Biocept more accurately as focusing exclusively on Biocept's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Biocept's intrinsic value based on its ongoing forecasts of Biocept's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Biocept's closest peers.
Biocept Cash |
|
Biocept Total Value Analysis
Biocept is currently forecasted to have takeover price of 4.96 M with market capitalization of 525, debt of 12.11 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Biocept fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
4.96 M | 525 | 12.11 M |
Biocept Investor Information
The company has price-to-book (P/B) ratio of 0.29. Some equities with similar Price to Book (P/B) outperform the market in the long run. Biocept recorded a loss per share of 96.34. The entity last dividend was issued on the 8th of September 2020. The firm had 1:30 split on the 17th of May 2023. Based on the key indicators related to Biocept's liquidity, profitability, solvency, and operating efficiency, Biocept is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Biocept Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Biocept has an asset utilization ratio of 83.76 percent. This connotes that the Company is making USD0.84 for each dollar of assets. An increasing asset utilization means that Biocept is more efficient with each dollar of assets it utilizes for everyday operations.Biocept Profitability Analysis
The company reported the revenue of 25.86 M. Net Loss for the year was (32.09 M) with loss before overhead, payroll, taxes, and interest of (14.3 M).About Biocept Valuation
The stock valuation mechanism determines Biocept's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Biocept based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Biocept. We calculate exposure to Biocept's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Biocept's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -3 M | -2.8 M | |
| Pretax Profit Margin | (1.12) | (1.18) | |
| Operating Profit Margin | (1.11) | (1.17) | |
| Net Loss | (1.12) | (1.17) | |
| Gross Profit Margin | (0.09) | (0.09) |
Biocept Current Valuation Indicators
Biocept's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Biocept's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Biocept, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Biocept's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Biocept's worth.Additional Tools for Biocept Stock Analysis
When running Biocept's price analysis, check to measure Biocept's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biocept is operating at the current time. Most of Biocept's value examination focuses on studying past and present price action to predict the probability of Biocept's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biocept's price. Additionally, you may evaluate how the addition of Biocept to your portfolios can decrease your overall portfolio volatility.